ModifiedUnitedHealthcarePolicy CS169.P

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea

Policy governing use and coverage of multiplex PCR gastrointestinal pathogen panel testing for evaluation of infectious diarrhea for UnitedHealthcare members; specifies clinical indications, target counts, and when testing is considered medically necessary or not.

Policy Summary

PayerUnitedHealthcare

PolicyGastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea

Policy CodePolicy CS169.P

Change TypeMaterial coverage criteria updates and CPT code refresh

Effective DateJul 1, 2025

Next Review Date

Key ActionOrder multiplex PCR panels only for patients meeting guideline-based indications and document symptoms/duration and blood culture status when using the 3–5 target pathway.

SourceLink

POLICY UPDATE CHANGES

Defines multiplex PCR panel testing up to five targets as medically necessary when performed with blood cultures for individuals with specified signs and symptoms.

Defines multiplex PCR panel testing up to 11 targets as medically necessary for evaluation of persistent diarrhea in higher-risk or immunocompromised individuals or when other stool studies have failed to yield a pathogen.

Multiplex PCR panel testing for all other indications and panels >11 targets are unproven and not medically necessary.

Updated list of applicable CPT codes to reflect quarterly edits; removed 0369U

3-5CPT 87505 definition (covered when criteria met)

6-11CPT 87506 definition (covered when criteria met)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

>11CPT 87507 (not medically necessary)

>7dDuration threshold

71%Mohtar et al. detection (25-pathogen)

archivedPrevious policy

Coverage Criteria for Multiplex GI Pathogen Panels

Medically necessary indications

Covered when ALL of the following are met

3-5 target panel pathway: Multiplex PCR panel testing of gastrointestinal pathogens including up to five targets when performed as part of an evaluation that includes blood cultures<=5 targets

AND the individual has ANY one of the following: diarrhea >7 days; diarrhea with fever, bloody/mucoid stools, severe abdominal cramping/tenderness, or signs of sepsis; OR suspected enteric fever with recent travel to an endemic region or exposure via food preparer with endemic exposure.

6-11 target panel pathway for persistent diarrhea: Multiplex PCR panel testing including up to 11 targets for the evaluation of persistent diarrhea in an individual at risk for C. difficile colitis OR who is immunocompromised OR when other stool diagnostic studies have failed to yield a pathogenic organism6-11 targets

Specific risk states include AIDS, use of immunosuppressive medications (post-transplant or for autoimmune disease), or other conditions causing immunosuppression; AND presence of diarrhea >7 days or diarrhea with fever, bloody/mucoid stools, severe abdominal cramping/tenderness, or signs of sepsis.

Indications aligned with clinical guidelines

Covered when testing is consistent with guideline-recommended clinical indications

Primary indications: Testing indicated for individuals with moderate-to-severe, bloody, febrile, dysenteric, nosocomial, or persistent diarrhea (>7 days), or immunocompromised hosts

Derived from ACG and IDSA guideline statements

Parallel culture and public health/susceptibility needs

Additional testing considerations

Organism-specific considerations: Use culture (or enrichment culture) in parallel for Salmonella when PCR/NAAT is used; consider culture when antimicrobial susceptibility testing or public health subtyping is required

Supported by studies showing discordance and guideline comments recommending parallel culture for certain bacterial pathogens

Clinical coverage criteria

Covered when testing aligns with clinical indications and guideline-based scenarios

Immunocompromised or severe illness: People who are immunocompromised with diarrhea should have a broad differential and evaluation of stool by culture, viral studies, and examination for parasites; obtain blood cultures when signs of septicemia or systemic infection are present.

Strong recommendation; moderate evidence

Traveler's diarrhea: Diagnostic testing is not recommended for most uncomplicated traveler's diarrhea unless treatment is indicated; evaluate for intestinal parasitic infections when diarrhea persists >=14 days; test for C. difficile if antimicrobial treatment occurred within the prior 8-12 weeks.>=14 days; 8-12 weeks

Strong recommendation; moderate evidence

Enteric fever or diarrhea with bacteremia: Perform culture-independent multiplex molecular diagnostics and, when indicated, culture-dependent diagnostic testing for suspected enteric fever or diarrhea with bacteremia.

Multiplex PCR panel testing of gastrointestinal pathogens for indications other than those listed in the medically necessary criteria and multiplex PCR panels with >11 targets are considered unproven and not medically necessary.

Routine diagnostic testing is generally not indicated for noninflammatory, self-limited acute gastroenteritis of limited duration. Following guideline-recommended criteria (for example, testing for dysentery, moderate-to-severe disease, or symptoms lasting >7 days) reduces unnecessary testing without reducing clinical yield.

Diagnostic testing is not recommended in most cases of uncomplicated traveler’s diarrhea unless treatment is indicated. Travelers with diarrhea lasting <14 days and without indication for antimicrobial therapy typically do not require stool testing.

Multiplex PCR panel testing of gastrointestinal pathogens for all other indications not specified in the covered criteria, and multiplex PCR panels with >11 targets, are considered unproven and not medically necessary.

Testing in low-risk individuals without fever, bloody stools, severe symptoms, immunocompromise, or prolonged duration is of low clinical yield and may produce additional positive findings of uncertain clinical significance; such testing is discouraged unless clinical criteria supporting testing are documented.

Routine testing of uncomplicated traveler’s diarrhea (when there is no indication for treatment) is not recommended and may be considered not medically necessary. Evaluate travelers with diarrhea lasting >= 14 days for parasitic infections or if recent antimicrobial exposure raises concern for C. difficile.

Indications Considered Medically Necessary

Evaluation of moderate-to-severe, bloody, febrile, dysenteric, nosocomial, or persistent diarrheal illnesses; immunocompromised individuals; suspected enteric fever with appropriate travel/exposure history.

Covered clinical scenarios: Evaluation of moderate-to-severe, bloody, febrile, dysenteric, nosocomial, or persistent diarrheal illnesses; immunocompromised individuals; suspected enteric fever with appropriate travel or exposure history.

For bacterial pathogens, culture-independent methods are recommended when available; for persistent diarrhea consider parasite testing as multiplex panels may have limited parasite coverage.

Moderate-to-severe diarrhea, bloody diarrhea, fever, persistent diarrhea (>7 days), nosocomial diarrhea, immunocompromised patients, suspected enteric fever or diarrhea with bacteremia

Guideline-aligned indications: Moderate-to-severe diarrhea, bloody diarrhea, fever, persistent diarrhea (>7 days), nosocomial diarrhea, immunocompromised patients, suspected enteric fever or diarrhea with bacteremia

Aligns with IDSA and ACG guideline recommendations including testing for Salmonella, Shigella, Campylobacter, Yersinia, C. difficile, and STEC when indicated.

Applicable Procedure Codes and Panel Target Counts

Applicable CPT procedure codesCPT

87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87507	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

Updated applicable CPT codes (example removed)CPT

0369U

CPT code removed from applicable codes list

Panel target count

Panel target count (policy threshold)Covered when 3-11 targets per CPT definitions (CPT 87505 = 3-5 targets; CPT 87506 = 6-11 targets). Panels >11 targets (CPT 87507) are considered not medically necessary.

CPT 87505 descriptionInfectious agent detection by nucleic acid; gastrointestinal pathogen, multiple types or subtypes, 3-5 targets.

CPT 87506 descriptionInfectious agent detection by nucleic acid; gastrointestinal pathogen, multiple types or subtypes, 6-11 targets.

CPT 87507 status12-25 targets — considered unproven and not medically necessary when used outside specified indications.

Traveler diarrhea duration threshold

Traveler's diarrhea testing threshold

Provider Actions, Documentation, and Prior Authorization Notes

Prior Authorization

Code-level prior authorization/coverage guidance

Code-level prior authorization/coverage guidance: Use CPT 87505 (3-5 targets) and CPT 87506 (6-11 targets) is covered when the clinical criteria in this policy are met (see Testing Sequence and Required Clinical Documentation). Panels with >11 targets (e.g., CPT 87507 for 12-25 targets) are considered unproven and not medically necessary and are not covered.

Covered CPT: 87505 (3-5 targets) — covered when policy clinical criteria met
Covered CPT: 87506 (6-11 targets) — covered when policy clinical criteria met
Not covered: CPT 87507 (12-25 targets) — multiplex panels >11 targets are unproven/not medically necessary

Note

Guideline-aligned ordering recommended

Guideline-aligned ordering is recommended. Restrict ordering to patients who meet guideline-based indications such as fever, bloody stools, severe abdominal pain/cramping, signs of sepsis, persistent diarrhea (>7 days) or immunocompromised status. For travel-related illness, consider testing for suspected enteric fever after recent travel to endemic regions. Avoid routine testing for noninflammatory, self-limited acute gastroenteritis.

Ordering and Test Sequencing Requirements

Note

Order testing based on clinical presentation and consider concurrent cultures

Ordering should be guided by clinical presentation including symptom duration, severity, immunocompromised status, and travel history; when bacterial testing is indicated, use culture-independent methods if available but consider concurrent stool cultures because panels may not detect all bacteria.

Consider parasite testing for diarrhea persisting >7 days.
When viral targets are detected, interpret results cautiously in immunocompetent patients.

Documentation Required

Require documentation of guideline-based indications when ordering

Order multiplex panels only when the clinical presentation meets guideline-based criteria (fever, bloody stool, immunocompromised status, persistent symptoms); document these indications to support medical necessity.

Documentation of qualifying clinical features is advised for coverage.

Not Medically Necessary / Not Covered Uses

Multiplex PCR panels that include more than 11 targets and multiplex panel testing performed for indications not specified in the policy’s covered criteria are not covered as they are considered unproven and not medically necessary.

Use of multiplex gastrointestinal panels for broad screening of patients with low pretest probability or for 'test of cure' is discouraged. Panels may detect additional organisms of uncertain clinical importance and do not provide culture isolates needed for antimicrobial susceptibility testing or public health subtyping.

Testing for uncomplicated traveler’s diarrhea when no treatment indication is present is not covered. Reserve diagnostic testing for travelers with prolonged symptoms (for example, diarrhea lasting >= 14 days) or when treatment or further evaluation is indicated.

Definitions and Key Terms

Persistent diarrhea

DefinitionDiarrhea lasting more than seven days.

Usage in policyUsed as a criterion for broader panel testing (triggers consideration of multiplex PCR panels up to 5 or up to 11 targets depending on risk factors).

Clinical implicationFor diarrhea >7 days consider stool parasitic testing and broader diagnostic evaluation as panels may be limited for parasites.

Suspected enteric fever

DefinitionClinical suspicion for typhoid or paratyphoid (enteric fever) in individuals with recent travel to endemic regions or exposure via food handlers with recent endemic exposure.

Policy actionWhen enteric fever is suspected, perform both culture-independent (multiplex molecular) and culture-dependent testing as indicated.

Background and Evidence Context

Gastroenteritis can be caused by bacteria, viruses, protozoa, and parasites. Most acute noninflammatory diarrhea is self-limited and does not require diagnostic testing. Fecal diagnostic testing is indicated for moderate-to-severe, bloody, febrile, nosocomial, or persistent diarrhea (>7 days), for immunocompromised individuals, and when enteric fever is suspected based on travel or exposure history. Culture-independent multiplex molecular assays increase pathogen detection and reduce turnaround time but have limitations, including the potential to detect nonviable organisms and the lack of culture isolates for susceptibility testing and public health subtyping.

Frequency Limits

Frequency limits

Frequency limits statusNo explicit frequency limits stated in this portion of the document.

ImplicationPolicy does not impose test frequency restrictions; ordering should follow clinical indications and guidelines.

DocumentationProviders should document clinical justification for repeat testing based on symptoms and guideline-based indications.

Laboratory certification / clearance

Lab certification requirementsNot specified in this document.

FDA-cleared panelsFDA-cleared commercial multiplex PCR kits exist (examples listed in FDA 510(k) database), but FDA clearance alone is informational and not a basis for coverage.

Policy Summary

PayerUnitedHealthcare

PolicyGastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea

Policy CodePolicy CS169.P

Change TypeMaterial coverage criteria updates and CPT code refresh

Effective DateJul 1, 2025

Next Review Date

Key ActionOrder multiplex PCR panels only for patients meeting guideline-based indications and document symptoms/duration and blood culture status when using the 3–5 target pathway.

SourceLink

On This Page

Strong recommendation; moderate evidence

Result interpretation caution: Interpret multiple-pathogen NAAT results with clinical context because assays detect nucleic acid and may not indicate viable organisms or clinical disease.

Strong recommendation; low evidence

Immunocompromised patients with diarrhea; travelers with prolonged diarrhea (>=14 days); suspected enteric fever or diarrhea with bacteremia; patients with systemic manifestations of infection.

High-risk populations and special testing thresholds: Immunocompromised patients with diarrhea; travelers with prolonged diarrhea (>=14 days) should be evaluated for parasitic infections; suspected enteric fever or diarrhea with bacteremia should prompt both molecular and culture-dependent testing; test for C. difficile in travelers treated with antimicrobials within the prior 8-12 weeks.>=14 days; 8-12 weeks

Recommendations derived from IDSA guideline statements; obtain blood cultures for suspected enteric fever or systemic infection.

>= 14 days — travelers with diarrhea lasting 14 days or longer should be evaluated for intestinal parasitic infections.

When to consider parasitic testingConsider parasite testing for travelers with prolonged diarrhea (>=14 days) as multiplex panels may be limited for parasites.

Implication for uncomplicated casesDiagnostic testing is not recommended in most uncomplicated traveler’s diarrhea unless treatment is indicated.

Recent antimicrobial exposure window for C. difficile testing

C. difficile testing window after antimicrobialsTest for C. difficile if travelers were treated with antimicrobials within the preceding 8-12 weeks.

Rationale from guidelinesACG recommends algorithms to distinguish colonization from infection; consider recent antimicrobial exposure when testing for CDI.

Documentation noteDocument recent antimicrobial exposure (within prior 8-12 weeks) when ordering C. difficile testing per policy guidance.

Follow IDSA/ACG/2016 and 2024 guideline indications: moderate-to-severe, bloody, febrile, dysenteric, nosocomial, or persistent diarrhea, or immunocompromised patients
Do not routinely test noninflammatory, short-duration gastroenteritis

Denial Risk

Denial for non-covered indications or >11 targets

Denial for non-covered indications or >11 targets: Claims for multiplex PCR panels performed for indications not specified in the policy (e.g., uncomplicated acute self-limited diarrhea without risk factors) or for panels that include more than 11 targets will be considered not medically necessary and subject to denial.

Multiplex PCR panel testing for indications other than those specified in this policy — not medically necessary
Multiplex PCR panels >11 targets (e.g., CPT 87507) — not medically necessary

Denial Risk

Potential inappropriate testing

Potential inappropriate testing: Testing outside recommended clinical indications (for example, routine testing of uncomplicated traveler's diarrhea when treatment is not indicated, or testing mild/self-limited noninflammatory diarrheal illness) may yield low clinical utility, unnecessary costs, and may lead to incidental or unclear findings (e.g., detection of organisms of uncertain clinical significance).

Avoid testing for uncomplicated traveler's diarrhea unless treatment is indicated or diarrhea is prolonged (>=14 days)
Avoid viral-target panels in immunocompetent patients with self-limited illness unless infection-control or immunocompromised status justifies testing

Note

Clinical-guided testing

Clinical-guided testing: Testing decisions should follow clinical guidance. Use culture-independent molecular methods for bacterial pathogens when testing is indicated, but consider parallel or confirmatory culture/enrichment culture for Salmonella and other organisms when clinically relevant. Reserve additional culture-dependent testing for cases where culture is indicated (e.g., outbreak investigation, public health reporting, or when antibiotic susceptibility and isolate recovery are required).

When PCR/NAAT is used for Salmonella detection, consider parallel enrichment culture due to variable sensitivity/specificity
Use culture or culture-based methods in addition to NAAT when isolate recovery or public health confirmation is needed

Documentation Required

Required clinical documentation

Required clinical documentation: Document clinical features that justify testing according to guideline-aligned indications. Acceptable documentation should include symptom type and duration (e.g., diarrhea >7 days, or >=14 days for travel-related parasitic evaluation), presence of fever, bloody or mucoid stools, severe abdominal cramping or tenderness, signs of sepsis, immunocompromised status, recent hospitalization (nosocomial onset), or recent travel to enteric fever–endemic areas.

Document duration of diarrhea and relevant symptomology (fever, bloody stools, severe abdominal pain, signs of sepsis)
Document immunocompromised status, recent hospitalization >3 days, recent antibiotic use (for C. difficile consideration), or recent travel to endemic regions for enteric fever

Note

Testing sequence

Testing sequence: When pathogen testing is indicated, culture-independent NAAT/multiplex panels are recommended for bacterial pathogens when available, but may be supplemented by culture-based methods as clinically indicated. For persistent diarrhea (>7 days), consider parasitic testing. For suspected C. difficile, follow two-step algorithms per ACG guidance to distinguish colonization from active infection. For Salmonella detection by NAAT, perform parallel enrichment culture when necessary for confirmation or susceptibility testing.

Use NAAT/multiplex assays for bacterial pathogen detection when indicated and available
Supplement NAAT with culture/enrichment culture for Salmonella or when isolate recovery is needed
For C. difficile, use a two-step testing algorithm (high sensitivity + high specificity modalities) per ACG guidance
Consider parasitic testing for diarrhea >7 days or travel-related illness

Note

Include both molecular and culture-dependent tests for enteric fever/bacteremia

Base orders on clinical suspicion and guideline-directed scenarios; in suspected enteric fever or bacteremia include both molecular multiplex testing and culture-dependent testing (blood and/or stool cultures) when indicated.

Obtain blood cultures for suspected enteric fever or systemic infection in addition to molecular testing.

When to obtain blood culturesObtain blood cultures when enteric fever is suspected or in people with signs of septicemia or systemic infection.

NAAT / multiplex molecular panel

DefinitionNucleic acid amplification test (NAAT) / multiplex molecular panel detects multiple enteric pathogens simultaneously.

Performance noteHigh sensitivity and faster turnaround compared with culture, but may detect nucleic acid from nonviable organisms or colonization.

Interpretation cautionClinical correlation is required because detection does not always indicate viable pathogen or need for therapy.

Culture-independent testing

DefinitionCulture-independent testing includes panel-based multiplex molecular diagnostics from stool (and blood) specimens.

RecommendationWhen available, culture-independent methods are recommended for detection of bacterial pathogens for indicated patients.

LimitationThese methods may not replace culture when susceptibility testing or public health subtyping is required.

Enteric fever

DefinitionEnteric fever: clinical syndrome (typhoid/paratyphoid) where clinical suspicion warrants both culture-independent and culture-dependent testing.

Testing approachPerform multiplex molecular diagnostics and, when indicated, culture-dependent testing and blood cultures for suspected enteric fever or diarrhea with bacteremia.

Epidemiologic contextConsider travel history to endemic regions or contact with travelers/food handlers from endemic areas when assessing risk.

Action for providersSearch FDA 510(k) database for specific panel clearances (Product Codes PCH and PCI) if needed.

Frequency/coverage specifics

Reimbursement/frequency specified?Not specified in this section.

Ordering guidanceOrder testing based on clinical presentation per guidelines; documentation of indications is advised.

Coverage implicationAbsence of explicit frequency limits means coverage determinations rely on clinical criteria and medical necessity rules in the policy.